← board
NGEN
NervGen Pharmadistress 2/10 · well-funded / low risk$1.71-1%today-71% from 52w high
Lead: Spinal Cord Injuries
Revenue
pre-revenue
Liquidity
$22M
Runway
1.1 yrs
Shares 1y
—
Price & events
-67.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
+2.1%
1W
-17.2%
1M
-56.6%
3M
-66.4%
6M
-38.8%
1Y
-20.0%
2Y
+13.7%
5Y
-2.6%
All
Overview
- Market Cap
- $135.80M
- Volume
- 31.33K
- 52 Week Range
- $1.67 – $5.97
- Total Shares
- 79.65M
- Float Shares
- 72.80M
- % Held by Insiders
- 20.33%
- % Held by Institutions
- 2.08%
- RVOL
- 0.04x
- Beta
- 0.69
Pipeline stages · 1 programs
NVG-291
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-12-31 | Phase 1/2 | NVG-291 | Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury | 24 | completed |
Catalyst news & presentations · 1
- 2026-08-25earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $11 (+522% upside) · 7 analysts
- 2026-07-14HC Wainwright & Co.Buy
- 2026-07-13Leerink PartnersOutperform
- 2026-04-27HC Wainwright & Co.Buy
Competitors — Spinal Cord Injuries
- none identified
Recent news
- 2026-07-21Certain Common Shares of NervGen Pharma Corp. are subject to a Lock-Up Agreement Ending on 21-JUL-2026. - marketscreener.com
- 2026-07-16HC Wainwright Lowers Earnings Estimates for NervGen Pharma - MarketBeat
- 2026-07-14H.C. Wainwright cuts NervGen stock price target to $15 on dilution - Investing.com Australia
- 2026-07-14H.C. Wainwright cuts NervGen stock price target to $15 on dilution - Investing.com India
- 2026-07-14H.C. Wainwright cuts NervGen stock price target to $15 on dilution - Investing.com
- 2026-07-14H.C. Wainwright cuts NervGen stock price target to $15 on dilution - Investing.com Canada
- 2026-07-14H.C. Wainwright cuts NervGen stock price target to $15 on dilution - Investing.com UK
- 2026-07-14NGEN Maintains Buy Rating by HC Wainwright & Co. -- Price Target Lowered to $15.00 - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.